Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

According to the article, that investor aims to influence the company's choice of a chief executive.

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...